解毒活血方对实验性萎缩性胃炎大鼠TXB_2和6-Keto-PGF_1a的影响  

Detoxification Activating Blood on the Experimental Rats Atriphic Gastritis of TXB_2 and 6-Keto-PGF_1a

作　　者：黄东华[1] 张彩[1] 李赫楠[1] 周俊琴[1] 

机构地区：[1]河北医科大学中医学院中医诊断教研室,河北石家庄050091

出　　处：《河北医学》2009年第11期1261-1263,共3页Hebei Medicine

基　　金：河北省科技厅课题(05276101D-75)

摘　　要：目的:探讨解毒活血方治疗萎缩性胃炎的作用机制。方法:将健康Wistar大鼠,随机分为正常对照组、模型对照组、解毒活血方治疗组、三九胃泰对照组,维酶素对照组。对各组采取不同的干预因素,按要求取材后,检测各组大鼠血浆血栓素B2和6-酮-前列腺素F1a的含量。结果:和模型组比较,实验组大鼠血栓素B2的含量明显降低(P<0.01),6-酮-前列腺素F1a的含量明显升高(P<0.01)。结论:解毒活血方通过降低血栓素B2的含量,升高6-酮-前列腺素F1a的含量,改善了萎缩性胃炎的血瘀情况,从而达到治疗萎缩性胃炎的目的。Objectlve： To investigate the Huoxue detoxification treatment for chronic atriphic gastritis mechanism. Method： Healthy wistar rats were randomly divided into normal control group, the model group, the treatment group with Huoxue detoxification, control group and peacekeepers in the control group. Each group taken on different interventions, based on request, in plasma were measured plasma thromboxane B2 and 6 - Keto - PGF1a content. Result： Comparison of the model group and the experimental group plasma thromboxane B2 level was significantly lower （ P 〈 0. 01 ）, 6 - Keto - PGF1 a content increased significantly （ P 〈 0.01 ）. Conclusion ： Huoxue detoxification side by regulating thromboxane B2 and 6 - Keto - PGF1a the levels, improve blood stasis atriphic gastritis, to achieve the treatment of chronic atriphic gastritis result.

关 键 词：解毒活血方 萎缩性胃炎 血栓素B2 6-酮-前列腺素F1A 

分 类 号：R285.5[医药卫生—中药学]